COMP <GO>
TECH vs RGEN // DIVIDEND YIELD & FCF PAYOUT SAFETY
Bio-Techne Corp (NASDAQ) VS. Repligen Corporation (NASDAQ) • 15-METRIC TALLY: TECH 9
— RGEN 3
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: TECH
LAST: $72.66 (-0.07%) • MKT CAP: $11.40B
dividend-safety
0.44%
LAST: $176.94 (-6.20%) • MKT CAP: $10.69B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TECH VS. RGEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TECH | RGEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.80% | 88.20% | -23.40 | RGEN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.40% | 2.30% | +1.10 | TECH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 91.3x | 95.0x | -3.70 | TECH | /valuation <GO> |
| Free Cash Flow Yield | 2.25% | 0.88% | +1.37 | TECH | /fcf-yield <GO> |
| Operating Margin | 8.40% | 1.80% | +6.60 | TECH | /operating-margins <GO> |
| Net Profit Margin | 6.00% | 1.60% | +4.40 | TECH | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | -3.30% | +8.50 | TECH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.44% | 0.00% | +0.44 | TECH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.12 | 9.31 | -2.19 | RGEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.3 | 56.7 | +2.60 | TECH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.04 | -0.16 | RGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.40B | $10.69B | $707.7M | TECH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TECH REV | RGEN REV | TECH GROSS % | RGEN GROSS % | TECH FCF | RGEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.22B | $0 | 64.8% | — | $256.6M | $93.9M |
| FY 2024 | $1.16B | $0 | 66.4% | — | $236.1M | $149.7M |
| FY 2023 | $1.14B | $0 | — | — | $203.2M | $113.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TECH // BETA 0.88
RGEN // BETA 1.04